EQS-Ad-hoc: MEDICLIN AG / Key word(s): Forecast/Annual Results Offenburg, 21 January 2025
MEDICLIN raises full-year guidance for the 2024 financial year MEDICLIN Aktiengesellschaft (Ticker: MED) announces that it is raising its guidance for the 2024 financial year. Instead of a Group EBIT* between EUR 33.0 and 39.0 million, MEDICLIN now expects a Group EBIT between EUR 48.0 and 54.0 million. The sales forecast for the Group was raised from -2.0 % to 0.0 % to now 1.0 % to 3.0 %. The preliminary figures for the fourth quarter and the 2024 financial year will be published on 27 February 2025. * As defined on the company's website at the following link Contact for further information: MEDICLIN Aktiengesellschaft Okenstraße 27 77652 Offenburg Ender Gülcan Head of Investor Relations and Sustainability Tel.: 0781/488-326 Fax: 0781/488-184 ender.guelcan@mediclin.de www.mediclin.de End of Inside Information
21-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | MEDICLIN AG |
Okenstraße 27 | |
77652 Offenburg | |
Germany | |
Phone: | +49 (0)781 488-326 |
Fax: | +49 (0)781 488-184 |
E-mail: | ender.guelcan@mediclin.de |
Internet: | www.mediclin.de |
ISIN: | DE0006595101 |
WKN: | 659510 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2071983 |
End of Announcement | EQS News Service |
|
2071983 21-Jan-2025 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.